gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'- reactive, tumoricidal T cells using high-affinity, altered peptide ligand

Journal of Experimental Medicine

Volumn 188, Issue 2, 1998, Pages 277-286

  Overwijk, Willem W ^a   Tsung, Allan ^a   Irvine, Kari R ^a   Parkhurst, Maria R ^a   Goletz, Theresa J ^a   Tsung, Kangla ^b   Carroll, Miles W ^c   Liu, Chunlei ^a   Moss, Bernard ^c   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CD8+ T lymphocyte; Gp100; Melanoma; Tumor associated antigen; Xenoimmunization

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; FEMALE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; VACCINE PRODUCTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; LIGANDS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PROTEINS; TUMOR ESCAPE;

EID: 0031852722     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.2.277     Document Type: Article

References (48)

1. Boon, T., P.G. Coulie, and B. Van Jen Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today. 18:267-268.
2. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:175-182.
3. Restifo, N.P. 1996. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8:658-663.
4. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell. 49:273-280.
5. Sant'Angelo, D.B., P.G. Waterbury, B.E. Cohen, W.D. Martin, L. Van Kaer, A.C. Hayday, and C.A. Janeway, Jr. 1997. The imprint of intrathymic self-peptides on the mature T cell receptor repertoire. Immunity. 7:517-524.
6. Hu, Q., W.C. Bazemore, C. Girao, J.T. Opferman, J. Sun, J. Shabanowitz, D.F. Hunt, and P.G. Ashton-Rickardt. 1997. Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. Immunity. 7:221-231.
7. Schwartz, R.H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351-357.
8. Wallace, P.M., J.N. Rodgers, G.M. Leytze, J.S. Johnson, and P.S. Linsley. 1995. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 154:5885-5895.
9. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
10. Kwon, B.S., R. Halaban, S. Ponnazhagan, K. Kim, C. Chintamaneni, D. Bennett, and R.T. Pickard. 1995. Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17. Nucleic Acids Res. 23:154-158.
11. Zhai, Y., J.C. Yang, P. Spiess, M.I. Nishimura, W.W. Overwijk, B. Roberts, N.P. Restifo, and S.A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20:15-25.
12. Overwijk, W.W., D.R. Surman, K. Tsung, and N.P. Restifo. 1997. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods (Orlando). 12:117-123.
13. Ljunggren, H.G., N.J. Stam, C. Ohlen, J.J. Neefjes, P. Hoglund, M.T. Heemels, J. Bastin, T.N. Schumacher, A. Townsend, and K. Karre. 1990. Empty MHC class I molecules come out in the cold. Nature. 346:476-480.
14. Earl, P.L., N. Cooper, and B. Moss. 1991. Preparation of cell cultures and vaccinia virus stocks. Curr. Prot. Mol. Biol. 16: 1-117.
15. Chakrabarti, S., J.R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 23:1094-1097.
16. Bronte, V., M.W. Carroll, T.J. Goletz, M. Wang, W.W. Overwijk, F. Marincola, S.A. Rosenberg, B. Moss, and N.P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA. 94:3183-3188.
17. Yamamoto, H. 1987. Cloning and sequencing of mouse tyrosinase cDNA. Jpn. J. Genet. 62:271-274.
18. Shibahara, S., Y. Tomita, T. Sakakura, C. Nager, B. Chaudhuri, and R. Muller. 1986. Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res. 14: 2413-2427.
19. Jackson, I.J., D.M. Chambers, K. Tsukamoto, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, and V. Hearing. 1992. A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO (Eur. Mol. Biol. Organ.) J. 11:527-535.
20. Surman, D.R., K.R. Irvine, E.P. Shulman, T.M. Allweis, S.A. Rosenberg, and N.P. Restifo. 1998. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J. Immunol. Methods. In press.
21. Kobayashi, T., K. Urabe, S.J. Orlow, K. Higashi, G. Imokawa, B.S. Kwon, B. Potterf, and V.J. Hearing. 1994. The Pmel 17/ silver locus protein. Characterization and investigation of its melanogenic function. J. Biol. Chem. 269:29198-29205.
22. Winder, A., T. Kobayashi, K. Tsukamoto, K. Urabe, P. Aroca, K. Kameyama, and V.J. Hearing. 1994. The tyrosinase gene family - interactions of melanogenic proteins to regulate melanogenesis. Cell Mol. Biol. Res. 40:613-626.
23. Irvine, K.R., J.B. Rao, S.A. Rosenberg, and N.F. Restifo. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156:238-245.
24. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA. 93:11341-11348.
25. Mamula, M.J. 1995. Lupus autoimmunity: from peptides to particles. Immunol. Rev. 144:301-314.
26. Kozhich, A.T., R.R. Caspi, J.A. Berzofsky, and I. Gery. 1997. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. J. Immunol. 158:4145-1151.
27. Fong, L., C.L. Ruegg, D. Brockstedt, E.G. Engleman, and R. Laus. 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159: 3113-3117.
28. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
29. Parker, K.C., M.A. Bednarek, and J.E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163-175.
30. Rammensee, H.G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
31. Vanderlugt, C.J., and S.D. Miller. 1996. Epitope spreading. Curr. Opin. Immunol. 8:831-836.
32. Moudgil, K.D., T.T. Chang, H. Eradat, A.M. Chen, R.S. Gupta, E. Brahn, and E.E. Sercarz. 1997. Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. J. Exp. Med. 185:1307-1316.
33. Mamula, M.J., S. Fatenejad, and J. Craft. 1994. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152:1453-1461.
34. Mamula, M.J., R.H. Lin, C.A. Janeway, Jr., and J.A. Hardin. 1992. Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J. Immunol. 149:789-795.
35. Simitsek, P.D., D.G. Campbell, A. Lanzavecchia, N. Fairweather, and C. Watts. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957-1963.
36. Deng, Y., J.W. Yewdell, L.C. Eisenlohr, and J.R. Bennink. 1997. MHC affinity, peptide liberation. T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1507-1515.
37. Eisenlohr, L.C., I. Bacik, J.R. Bennink, K. Bernstein, and J.W. Yewdell. 1992. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell. 71:963-972.
38. Restifo, N.P., I. Bacik, K.R. Irvine, J.W. Yewdell, B.J. McCabe, R.W. Anderson, L.C. Eisenlohr, S.A. Rosenberg, and J.R. Bennink. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:4414-4422.
39. Ke, Y., and J.A. Kapp. 1996. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J. Exp. Med. 184:1179-1184.
40. Fuchs, E.J., and P. Matzinger. 1992. B cells turn off virgin but not memory T cells. Science. 258:1156-1159.
41. Abbas, A.K., S. Haber, and K.L. Rock. 1985. Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting 13 lymphocytes, and function of immunoglobulin receptors. J. Immunol. 135: 1661-1667.
42. Mamula, M.J. 1993. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J. Exp. Med. 177:567-571.
43. Parkhurst, M.R., M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539-2548.
44. 43a. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwartz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
45. Lipford, G.B., S. Bauer, H. Wagner, and K. Heeg. 1995. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine. 13:313-320.
46. Pogue, R.R., J. Eron, J.A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*1201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA. 92:8166-8170.
47. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
48. Liu, G.Y., P.J. Fairchild, R.M. Smith, J.R. Prowle, D. Kioussis, and D.C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3:407-415.